Advertisement

Organisation › Details
Moderna Inc. (Nasdaq: MRNA)
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators. Headquartered in Cambridge, Mass., with a European headquarters in Basel, Switzerland, Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. *
![]() |
Start | 2018-08-01 renamed |
Group | Moderna (Group) | |
Predecessor | Moderna Therapeutics Inc. | |
![]() |
Industry | mRNA-based drug |
Industry 2 | mRNA technology | |
![]() |
Person | Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly) |
Person 2 | Kim, Lorence H. (Moderna 201903 CFO) | |
![]() |
Region | Cambridge, MA |
Country | United States (USA) | |
Street | 200 Technology Square | |
City | 02139 Cambridge, MA | |
Tel | +1-617-714-6500 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | E: 501 to 1,000 (2020-02-12) |
Currency | USD | |
Annual sales | 60,209,000 (revenue, total, consolidated (2019) 2019-12-31) | |
Profit | -514,021,000 (2019-12-31) | |
Cash | 1,103,000,000 (2019-12-31) | |
* Document for �About Section�: Moderna, Inc.. (9/16/20). "Press Release: Moderna Announces First Commercial Organization Outside North America in Switzerland". Cambridge, MA. | ||
Record changed: 2022-05-02 |
Advertisement

More documents for Moderna (Group)
- [1] Moderna, Inc.. (4/27/22). "Press Release: Arpa Garay Joins Moderna as Chief Commercial Officer". Cambridge, MA....
- [2] Metagenomi Inc.. (11/2/21). "Press Release: Metagenomi and Moderna Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics". Emeryville, CA & Cambirdge, MA....
- [3] Moderna, Inc.. (9/3/21). "Press Release: Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster". Cambridge, MA....
- [4] Moderna, Inc.. (9/2/21). "Press Release: Moderna to Present at Upcoming Investor Conferences in September 2021". Cambridge, MA....
- [5] Moderna, Inc.. (6/28/21). "Press Release: Kate Cronin to Join Moderna as Chief Brand Officer on July 12". Cambridge, MA....
- [6] Moderna, Inc.. (6/1/21). "Press Release: Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands". Albstadt....
- [7] Moderna, Inc.. (5/19/21). "Press Release: Moderna to Establish an International Business Services Hub in Warsaw, Poland. Entity Complements Six Commercial Entities in Europe". Cambridge, MA....
- [8] DNA Script. (4/27/21). "Press Release: DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA". Paris & Cambridge, MA....
- [9] Flagship Pioneering. (1/12/21). "Press Release: Flagship Pioneering Launches Pioneering Medicines". Cambridge, MA....
- [10] Moderna, Inc.. (1/6/21). "Press Release: European Commission Authorizes COVID-19 Vaccine Moderna in Europe". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top